dual anti-MUC16 CAR T-cell therapy/PD-1 checkpoint inhibitor (Eureka Therapeutics/Memorial Sloan-Kettering Cancer Center)

N/A

Report date: 2025/03/19 09:00:08

Base Information

Drug Namedual anti-MUC16 CAR T-cell therapy/PD-1 checkpoint inhibitor (Eureka Therapeutics/Memorial Sloan-Kettering Cancer Center)
Drug Alias Namedual anti-MUC16 CAR T-cell therapy/secreted anti-PD-1 scFv (Eureka Therapeutics/Memorial Sloan-Kettering Cancer Center)
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapyBiologics > Protein drugs > Recombinant protein > Fusion proteinBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody fragment
Mechanisms of ActionProgrammed cell death protein 1 blockersMucin-16 modulators
TargetsMucin-16Programmed cell death protein 1
Therapy Area/IndicationsSolid tumours
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesEureka Therapeutics Inc
China Registration ClassN/A

Develop Information

Active CompaniesMemorial Sloan Kettering Cancer CenterEureka Therapeutics Inc
Inactive CompaniesN/A
Active IndicationsSolid tumours
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A